Product Information
Registration Status: ActiveSIN01607P
AMOXAPEN 250 CAPSULE 250mg is approved to be sold in Singapore with effective from 1988-01-06. It is marketed by GOLDPLUS UNIVERSAL PTE LTD, with the registration number of SIN01607P.
This product contains Amoxycillin 250mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by REMEDICA LTD in CYPRUS.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as it is susceptible to beta-lacatamase degradation.
Indication
For the treatment of infections of the ear, nose, and throat, the genitourinary tract, the skin and skin structure, and the lower respiratory tract due to susceptible (only b-lactamase-negative) strains of Streptococcus spp. (a- and b-hemolytic strains only), S. pneumoniae, Staphylococcus spp., H. influenzae, E. coli, P. mirabilis, or E. faecalis. Also for the treatment of acute, uncomplicated gonorrhea (ano-genital and urethral infections) due to N. gonorrhoeae (males and females).
Mechanism of Action
Amoxicillin binds to penicillin-binding protein 1A (PBP-1A) located inside the bacterial cell well. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor.
Pharmacokinetics
- Absorption
- Rapidly absorbed after oral administration.
- Distribution
- Metabolism
- Hepatic metabolism accounts for less than 30% of the biotransformation of most penicillins
- Elimination
Toxicity
Serious toxicity is unlikely following large doses of amoxicillin. Acute ingestion of large doses of amoxicillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.
Active Ingredient/Synonyms
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | 6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid | Amox | Amoxicilina | Amoxicillin (anhydrous) | Amoxicillin anhydrous | Amoxicilline | Amoxicillinum | Amoxycillin | AX | p-Hydroxyampicillin | α-amino-p-hydroxybenzylpenicillin | Amoxicillin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.